Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cephalexin
Drug ID BADD_D00412
Description Cephalexin is the first of the first generation cephalosporins.[A179071,A179074] This antibiotic contains a beta lactam and a dihydrothiazide.[A179071] Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,Label] Cephalexin was approved by the FDA on 4 January 1971.[L6547]
Indications and Usage For the treatment of respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes; otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis; skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes; bone infections caused by Staphylococcus aureus and/or Proteus mirabilis; genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.
Marketing Status Prescription; Discontinued
ATC Code J01DB01
DrugBank ID DB00567
KEGG ID D00263
MeSH ID D002506
PubChem ID 27447
TTD Drug ID D0Z5EM
NDC Product Code 68180-441; 63629-9207; 63629-9200; 63187-205; 54348-555; 69778-930; 61919-606; 68071-5241; 67877-255; 0093-2240; 0143-9897; 65862-018; 68071-3186; 42291-209; 68071-4233; 53002-2182; 80425-0121; 62135-480; 63629-9199; 68071-4516; 53002-2180; 65862-019; 63629-9205; 63629-7740; 50268-151; 67296-0976; 68180-440; 61919-049; 67877-219; 53002-2181; 50090-4423; 69778-931; 70934-840; 60687-163; 50090-0070; 63629-8857; 68071-2249; 68071-5038; 65862-338; 68180-122; 71205-591; 60687-152; 72969-116; 43063-536; 63629-7927; 24979-155; 80425-0005; 50090-3111; 42582-211; 24979-154; 63629-9198; 50090-3057; 42582-212; 68788-7529; 0093-4175; 72287-310; 68071-1585; 50090-4795; 63187-046; 0143-9898; 67877-545; 68071-4355; 50090-5196; 70518-3362; 51655-028; 67296-0037; 63629-7743; 54348-560; 43063-634; 80425-0006; 50268-152; 68071-2246; 68071-5016; 63629-7605; 50090-3291; 66267-982; 68788-7938; 70518-2273; 63629-8856; 0093-3145; 68788-7796; 68180-121; 0093-3147; 50090-3252; 42291-208; 63629-9202; 69043-009; 69043-008; 68788-9539; 42708-070; 42708-017; 50090-3199; 53002-2260; 50090-2749; 63629-9204; 63629-9203; 50090-3202; 63629-8854; 63629-8858; 0093-4177; 63629-8981; 68788-7761; 55289-058; 70518-3066; 43063-678; 70934-040; 68788-9326; 68071-4406; 67877-544; 42708-145; 67877-254; 59651-230; 45865-428; 53002-2540; 70518-3378; 63629-8855; 63629-9206; 0143-9769; 70518-3059; 68071-5011; 43744-061; 63629-9201; 43063-497; 62135-481; 0093-2238; 0143-9770; 50090-0219; 42708-100; 50090-0220; 63629-8980; 68071-4434; 50090-3427; 68788-9713; 68788-9538; 71205-553; 55289-057; 70934-082; 67877-220; 68071-4429; 76420-052
Synonyms Cephalexin | Cefalexin | Cephalexin Hydrochloride | Cephalexin Monohydrochloride, Monohydrate | Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer | Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer | Cephalexin, (6R-(6alpha,7beta))-Isomer | Cephalexin, Monosodium Salt | Cephalexin Monohydrochloride | Ceporexine | Palitrex | Cephalexin Monohydrate | Cephalexin Dihydride | Cephalexin Hemihydrate | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer
Chemical Information
Molecular Formula C16H17N3O4S
CAS Registry Number 15686-71-2
SMILES CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Joint swelling15.01.02.0040.000116%Not Available
Leukopenia01.02.02.001--Not Available
Lip dry07.06.01.0030.000116%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.000271%Not Available
Malaise08.01.01.003--
Mania19.16.02.0020.000155%
Metabolic acidosis14.01.01.0030.000077%Not Available
Migraine24.03.05.003; 17.14.02.0010.000077%Not Available
Mouth ulceration07.05.06.0040.000077%Not Available
Nausea07.01.07.0010.000620%
Nephropathy toxic12.03.01.010; 20.05.03.002--Not Available
Nervous system disorder17.02.10.001--Not Available
Neutropenia01.02.03.004--Not Available
Oedema peripheral14.05.06.011; 02.05.04.007; 08.01.07.0070.000077%
Osteoarthritis15.01.04.001--Not Available
Pain08.01.08.0040.000465%
Pain in extremity15.03.04.010--
Pancreatitis acute07.18.01.0020.000077%Not Available
Pancytopenia01.03.03.003--Not Available
Paronychia23.09.04.001; 11.01.12.0010.000077%
Pemphigoid23.03.01.004; 10.04.02.0020.000116%Not Available
Pneumonia22.07.01.003; 11.01.09.0030.000310%Not Available
Presyncope24.06.02.010; 17.02.05.009; 02.01.02.0070.000077%
Prothrombin level increased13.01.02.011--Not Available
Pruritus23.03.12.0010.000813%
Pruritus genital21.10.01.002; 23.03.12.008--Not Available
Pseudomembranous colitis07.19.01.003; 11.02.02.002--Not Available
Pulmonary embolism22.06.02.001; 24.01.06.0010.000194%Not Available
Pyrexia08.05.02.0030.000504%
Rash23.03.13.0010.001665%Not Available
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages